- Conditions
- BPD - Bronchopulmonary Dysplasia
- Interventions
- NAVA technology to synchronize NIPPV
- Device
- Lead sponsor
- New York Medical College
- Other
- Eligibility
- 24 Weeks to 30 Weeks
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Valhalla, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1825–1848
of 14,761
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- Placebo, cisplatin/carboplatin, onartuzumab, paclitaxel
- Drug
- Lead sponsor
- Genentech, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 34
- States / cities
- Huntsville, Alabama • Scottsdale, Arizona • Bakersfield, California + 28 more
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- DS-1062a, Docetaxel
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 605 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 32
- States / cities
- Chandler, Arizona • Anaheim, California • Glendale, California + 28 more
- Conditions
- Coronavirus Disease (COVID-19)
- Interventions
- Molnupiravir, Placebo
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,082 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 71
- States / cities
- Cullman, Alabama • Paradise Valley, Arizona • Phoenix, Arizona + 58 more
- Conditions
- Asthma
- Interventions
- Not listed
- Lead sponsor
- National Institute of Environmental Health Sciences (NIEHS)
- NIH
- Eligibility
- 15 Years to 50 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2001
- U.S. locations
- 1
- States / cities
- Worcester, Massachusetts
- Conditions
- Metastatic Non-Squamous Non-Small Cell Lung Cancer, Adult Solid Tumor
- Interventions
- Visugromab RDE (recommended dose for expansion), Visugromab 6mg/kg, Nivolumab, Placebo Saline Infusion, Docetaxel
- Biological · Other · Drug
- Lead sponsor
- CatalYm GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Los Angeles, California • Mineola, New York + 2 more
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Acapella Vibratory PEP Therapy Device plus usual care, Sham Acapella Vibratory PEP Device plus usual care
- Device
- Lead sponsor
- New York Presbyterian Brooklyn Methodist Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 91 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Covid19, Coronavirus Infection, SARS-CoV-2 Infection
- Interventions
- 0.9% w/v NaCL Saline, 1.5% w/v Hydrogen Peroxide, 0.12% Chlorohexidine Gluconate, 27% Ethanol plus essential oils, 0.5% w/v Povidone-iodide, 0.075% Cetylpyridinium Chloride
- Other · Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 128 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Insomnia
- Interventions
- Assisted Relaxation Therapy, Modified Assisted Relaxation Therapy
- Behavioral
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Breast Cancer, Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- Abraxane, Alimta
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2014
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Non Small Cell Lung Cancer
- Interventions
- Necitumumab, Gemcitabine, Cisplatin
- Biological · Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,093 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2024
- U.S. locations
- 15
- States / cities
- Chandler, Arizona • Fayetteville, Arkansas • Sacramento, California + 12 more
- Conditions
- Chronic Kidney Disease, Pulmonary Embolism, Renal Artery Stenosis, Pulmonary Cancer
- Interventions
- Low Volume iso-osmolar non-ionic radio contrast medium, Acetylcysteine Inhalation, Sodium Bicarbonate Solution, 64-MDCT Scanning
- Drug · Procedure
- Lead sponsor
- VA Greater Los Angeles Healthcare System
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2017
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Carcinoma, Non Small Cell Lung
- Interventions
- gemcitabine, carboplatin, cisplatin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Asthma
- Interventions
- Advair Diskus100/50 µg, Flovent Diskus 100 µg, Methacholine Chloride, Albuterol
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 4 Years to 11 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- COVID-19
- Interventions
- Document delays and frequencies of inadequate blood products for emergent cases
- Other
- Lead sponsor
- Methodist Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Lung Cancer, Gastrointestinal Cancer
- Interventions
- Standard of Care (Acute Cancer Care Center), Standard of Care (Goals of Care)
- Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Advanced Cancers
- Interventions
- lorlatinib
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 10
- States / cities
- Aurora, Colorado • Atlanta, Georgia • San Antonio, Texas
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- pulmonary function testing
- Procedure
- Lead sponsor
- Barbara Ann Karmanos Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Gastroesophageal Reflux, Chronic Obstructive Pulmonary Disease
- Interventions
- 24 hour pH testing
- Procedure
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Sarcoidosis-associated Pulmonary Hypertension
- Interventions
- Selexipag, Placebo
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 8
- States / cities
- Indianapolis, Indiana • New Orleans, Louisiana • New York, New York + 5 more
- Conditions
- Vaccine-Preventable Diseases, COVID-19 Pandemic, Health-Related Behavior, Health Knowledge, Attitudes, Practice, Narration
- Interventions
- Baseline surveys, Digital Storytelling Intervention, Information Control Intervention
- Behavioral
- Lead sponsor
- Arizona State University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Phoenix, Arizona
- Conditions
- Coronavirus Disease 2019
- Interventions
- Placebo, fostamatinib
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Falls Church, Virginia
- Conditions
- COVID-19
- Interventions
- Clazakizumab, Placebo
- Drug · Other
- Lead sponsor
- Columbia University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Influenza a, Influenza B, RSV, COVID 19
- Interventions
- LIAISON NES FLU A/B, RSV & COVID-19
- Diagnostic Test
- Lead sponsor
- DiaSorin Molecular LLC
- Industry
- Eligibility
- Not listed
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 3
- States / cities
- Henderson, Nevada • Pittsburgh, Pennsylvania • McAllen, Texas